Press Releases

Date Title View
Toggle SummaryMarch 2, 2020 GenMark Diagnostics Announces Global Shipments of ePlex® RUO Test Kits Designed for SARS-CoV-2 Detection
CARLSBAD, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus. 
View HTML
Toggle SummaryFebruary 18, 2020 GenMark Diagnostics to Participate in the Cowen Health Care Conference
CARLSBAD, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts
View HTML
Toggle SummaryFebruary 10, 2020 GenMark Diagnostics Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 2, 2020
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020. Management will hold a conference call to review the company's
View HTML
Toggle SummaryFebruary 10, 2020 GenMark Diagnostics Announces CEO and Chairman Transition
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel , Chief Operating Officer, has been appointed Interim President and Chief Executive
View HTML
Toggle SummaryJanuary 13, 2020 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2019
CARLSBAD, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019 .
View HTML
Toggle SummaryDecember 30, 2019 GenMark Diagnostics to Participate in the J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming J.P. Morgan Healthcare conference in San Francisco,
View HTML
Toggle SummaryNovember 13, 2019 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryNovember 6, 2019 GenMark Diagnostics Reports Third Quarter 2019 Results
CARLSBAD, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2019 .
View HTML
Toggle SummaryOctober 23, 2019 GenMark Diagnostics Schedules Third Quarter 2019 Financial Results Conference Call for November 6, 2019
CARLSBAD, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, November 6, 2019. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryAugust 5, 2019 GenMark Diagnostics Reports Second Quarter 2019 Results
CARLSBAD, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2019 . Highlights Recognized total revenue of $18.4
View HTML